Catalent Finalizes RheinCell Therapeutics Acquisition
Catalent finalizes their acquisition of iPSC developer and manufacturer RheinCell Therapeutics.
On August 4th, 2021, Catalent announced that they had finalized the acquisition of RheinCell Therapeutics, a manufacturer and developer of induced pluripotent stem cells (iPSC) technologies. The company had announced their principal agreement to acquire RheinCell on June 24th, 2021.
Founded in 2017, RheinCell research has broad applicability for cell-based therapies. As a stem cell, iSPCs can be differentiated into various cell types, which means they can be used for a variety of different cell therapies.
According to a company press release, RheinCell’s acquisition grants Catalent full good manufacturing practice (GMP) lines, non-GMP equivalent iPSC banks, and iSPC development and reprogramming. Catalent will now have accelerated access to high-quality iSPC banks and the ability to build on their existing iSPC services, among other things.
Source: Catalent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
